Fulgent Genetics(FLGT) - 2023 Q4 - Annual Report

Our consolidated cost of revenue decreased by $67.3 million, or 27$252.1 million in 2022 to $184.8 million in 2023. The decrease was primarily due to decreases of$32.1 million in consulting and outside labor costs for production, $25.9 million in reagent and supply expenses,$12.3 million in depreciation expenses, $5.3 million in shipping expenses, and$1.2 million in travel and meals expense and $2.9 million in facility expense, all related to decreased COVID-19 testing, and partially offset by an ...